JD Healthcare, a subsidiary of China’s e-commerce juggernaut JD.com (NASDAQ: JD), has formed a strategic partnership with Chongqing Genrix Bio Pharmaceutical Co., Ltd. This alliance combines Genrix Bio’s prowess in drug research and development with JD Healthcare’s extensive resource and ecological advantages in medical treatment, medication, health management, and insurance. Together, they aim to enhance online-offline integration, focusing on comprehensive services for doctors, patients, and pharmaceutical needs. The financial specifics of this partnership have not been disclosed.
Genrix Bio’s xeligekimab, an anti-IL-17 antibody approved to treat plaque psoriasis in China this August, is now available through JD Pharmacy’s DTP (direct to patient) stores. This collaboration will enable JD Healthcare and Genrix Bio to offer psoriasis patients a seamless online follow-up and prescription renewal process, complemented by offline medication adherence and injection services. Moreover, they will provide a one-stop “doctor-patient-drug” closed-loop service for ongoing disease management, addressing the holistic needs of patients.- Flcube.com
